Results CD~+_4 CD~+_(25)Treg cells comprised(13.5± 1.8)% of peripheral CD~+_4T cells in the blood of persistent hepatitis C virus infected patients,which was significantly higher than that of healthy controls(5.3±0.8)%(P=0.004).
Preoperative diagnosis was as follows:1.hepatic cirrhosis after viral hepatitis type B. 2.postoperation of liver transplantation infected viral hepatitis type C resulting from dysfunction of grafting liver. 3. Sclerosing cholangitis and liver failure.
The present study was undertaken to explore the prevalence and clinical features of viral hepatitis type C (HC) among children with non-A non-B hepatitis (NANBH). Anti-hepatitis C virus antibody (anti-HCV) and HCV RNA were detected in serum specimens of 57 children (1.7-14 years old) with NANBH by using ELISA and nested polymerase chain reaction (NPCR).
Results ANCA was negative in 58 healthy donors, but positive in 10.2%(4/39), 19%(20/105), 25%(10/40) and 15%(3/20) of patients with viral hepatitis A(VHA), viral hepatitis B (VHB), viral hepatitis C (VHC) and viral hepatitis E (VHE), respectirely.
RT-PCR was used to detect HGV-RNA. The result showed that the positive rate of serum HGV-RNA in blood donors, viral hepatitis C and non-A～non-E hepatitis patients were 6.4%(13/201),21.43%(9/24) and 8.33%(1/12), respectively.
Natural History of Acute Symptomatic Hepatitis Type C
Hepatitis type C virus infection in patients with type B chronic liver disease
On the other hand, these cells were detected in none of those who remained seronegative for anti-hepatitis B surface antigen, or in the 7 normal subjects or the 2 chronic hepatitis type C patients.
Interferon α therapy for chronic active hepatitis type C after renal transplantation and allograft rejection
Clinical, pathological, and virological analysisincluding hypervariable region-1 of hepatitis C virus(HCV) was performed to predict the effect of interferon(IFN) on 41 patients with chronic hepatitis type C.
Hepatitis C virus (HCV)-RNA in sera of patients with viral hepatitis C is supposed to be included, at least partially, into HCV particles.
Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum γ-glutamyltranspeptidase levels
We administered ursodeoxycholic acid (UDCA) orally, at a daily dose of 600 mg, for 4 months to 36 patients with chronic viral hepatitis C.
Another 36 patients with chronic viral hepatitis C, treated with placebo for 4 months, served as controls.
These results suggested that UDCA has the potential to reverse hepatocellular damage in patients with chronic viral hepatitis C, in whom high GGT levels may be due, in part, to a damaged interlobular bile duct.